Phospho mtor s2481

Manufactured by Cell Signaling Technology

Sourced in United States

Phospho-mTOR (S2481) is a lab equipment product from Cell Signaling Technology. It is an antibody that specifically recognizes the phosphorylated form of the mTOR protein at the serine 2481 residue.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Phospho-mTOR (186 citations)

3 protocols using phospho mtor s2481

Molecular Signaling Pathway Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tan IIA was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), Go 6983, tanespimycin (17-AAG) and ganetespib from Medchem Express (Monmouth Junction, NJ, USA). Antibodies specific for β-actin (#4970), Hsp70 (#4872), IKKα (#2682), EGFR (#4267), PKCα (#2056), PKCδ (#9616), PKCμ (#2052), PKCζ (#9368), PKCε (#2683), Phospho-c-Raf (#9427), c-Raf (#9422), Phospho-MEK1/2 (#9154), MEK1/2 (#8727), Phospho-Erk1/2 (#4370), Erk1/2 (#9102), Phospho-PI3K (#4228), PI3K (#4257), Phospho-Akt (#4060), Akt (#9272), Phospho-mTOR (S2448) (#5536), Phospho-mTOR (S2481) (#2974), mTOR (#2983), LC3B (#3868), Bcl-2 (#2872), PARP (#9542) and cleaved caspase-3 (#9661) were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-Hsp90 (#ab13492) and anti-Ras (#ab52939) antibodies were from Abcam (Cambridge, UK).

Lv C., Zeng H.W., Wang J.X., Yuan X., Zhang C., Fang T., Yang P.M., Wu T., Zhou Y.D., Nagle D.G, & Zhang W.D. (2018). The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell Death & Disease, 9(2), 165.

+ Open protocol

+ Expand

Western Blot Analysis of mTOR Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell extracts were prepared by scraping the cells with 60–80 μL of cold lysis buffer (Lee et al., 2014) and storing on ice for 10 min. Clearing of the homogenates, protein quantification, SDS/PAGE, western blotting, and quantification of blots were performed as described previously (Lee et al., 2009). The antibodies (Catalog number) against 4E‐BP1 (#9644), phospho‐4E‐BP1(T37/46) (#2855), phospho‐4E‐BP1(S65) (#9451), phospho‐4E‐BP1(T70) (#9455), 4E‐BP2 (#2845), AKT (#4691), phospho‐AKT(T308) (#2965), phospho‐AKT(S473) (#9271), eIF4A (#2013), eIF4A1 (#2490), eIF4B (#3592), phospho‐eIF4B(S422) (#3591), eIF4E (#2067), eIF4G (#2469), eIF4H (#3469), mLST8 (#3274), Raptor (#2280), Rictor (#2214), p70S6K (#2708), phospho‐p70S6K (T389) (#9205), STAT1 (#9172), phospho‐STAT1(Y701) (#9171), STAT3 (#4904), phospho‐STAT3(Y705) (#9131), phospho‐STAT3(S727) (#9134), mTOR (#2983), phospho‐mTOR(S2448) (#5536), and phospho‐mTOR(S2481) (#2974) were obtained from Cell Signal Technology (Danvers, MA, USA); GAPDH (#CSB‐MA000071M0m) was obtained from Cusabio (Houston, TX, USA).

Lee H., Chin H., Kim H., Jung H, & Lee D. (2020). STAT3‐mediated MLST8 gene expression regulates cap‐dependent translation in cancer cells. Molecular Oncology, 14(8), 1850-1867.

+ Open protocol

+ Expand

Protein Isolation and Western Blot Analysis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Total protein (~20 μg) was isolated from cells following 72 h treatment or vehicle control (0.02% DMSO or ethanol) for protein analysis as previously described (10 (link), 14 (link)). The following antibodies were used: ASCT2 (#5345), SNAT1/SLC38A1 (#36057), EAAT2/SLC1A2 (#3838), LAT1/SLC7A5 (#5347), phospho-p70S6K (T389) (#9234), p70SK (#9202), phospho-mTOR(S2448) (#5536), phospho-mTOR(S2481) (#2974), mTOR (#2983), phospho-AKT(S473) (#4058), AKT (#4691), ATG13 (#13273) were from Cell Signaling, Danvers, MA; SNAT2/SLCA2 (#bs-12125R) was from Bioss, Woburn, MA; phospho-ATG13(S318) (#NBP2-19127) was from Novus, Centennial, CO; loading control antibodies such as actin (#sc-47778) was from Santa Cruz Biotechnology, Santa Cruz, CA and β-tubulin (#T7816) was from Sigma.

Demas D.M., Demo S., Fallah Y., Clarke R., Nephew K.P., Althouse S., Sandusky G., He W, & Shajahan-Haq A.N. (2019). Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. Frontiers in Oncology, 9, 686.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!